Analysts Set Expectations for ITOS FY2029 Earnings

iTeos Therapeutics, Inc. (NASDAQ:ITOS) – Investment analysts at HC Wainwright issued their FY2029 EPS estimates for shares of iTeos Therapeutics in a research note issued on Thursday, March 6th. HC Wainwright analyst S. Ramakanth forecasts that the company will earn $1.19 per share for the year. HC Wainwright has a “Buy” rating and a $46.00 price objective on the stock. The consensus estimate for iTeos Therapeutics’ current full-year earnings is ($3.49) per share.

Other equities analysts have also recently issued research reports about the stock. Wells Fargo & Company dropped their price objective on shares of iTeos Therapeutics from $19.00 to $17.00 and set an “overweight” rating for the company in a research note on Thursday. Wedbush restated an “outperform” rating and issued a $25.00 price objective on shares of iTeos Therapeutics in a research note on Wednesday. Finally, JPMorgan Chase & Co. dropped their price objective on shares of iTeos Therapeutics from $22.00 to $15.00 and set an “overweight” rating for the company in a research note on Thursday.

iTeos Therapeutics Stock Performance

Shares of ITOS stock opened at $7.05 on Friday. iTeos Therapeutics has a 52-week low of $6.67 and a 52-week high of $18.75. The stock has a market cap of $257.56 million, a price-to-earnings ratio of -2.24 and a beta of 1.38. The firm has a fifty day moving average of $7.52 and a 200-day moving average of $9.42.

iTeos Therapeutics (NASDAQ:ITOS) last issued its quarterly earnings results on Wednesday, March 5th. The company reported ($1.01) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.14) by $0.13.

Institutional Investors Weigh In On iTeos Therapeutics

Hedge funds have recently made changes to their positions in the company. Point72 DIFC Ltd acquired a new stake in shares of iTeos Therapeutics during the 3rd quarter worth about $31,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of iTeos Therapeutics during the 4th quarter worth about $42,000. Virtus ETF Advisers LLC increased its position in shares of iTeos Therapeutics by 58.2% during the 4th quarter. Virtus ETF Advisers LLC now owns 8,948 shares of the company’s stock worth $69,000 after purchasing an additional 3,293 shares in the last quarter. Forefront Analytics LLC acquired a new stake in shares of iTeos Therapeutics during the 4th quarter worth about $85,000. Finally, Graham Capital Management L.P. acquired a new stake in shares of iTeos Therapeutics during the 4th quarter worth about $85,000. Institutional investors and hedge funds own 97.16% of the company’s stock.

iTeos Therapeutics Company Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.